PickupJ, KeenH. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care, 2002; 25:593–598.
2.
RabboneI, ScaramuzzaA, BobbioA, BonfantiR, IafuscoD, LombardoF, ToniS, TuminiS, CeruttiF. Insulin pump therapy management in very young children with type 1 diabetes using continuous subcutaneous insulin infusion. Diabetes Technol Ther, 2009; 11:707–709.
3.
PhillipM, BattelinoT, RodriguezH, DanneT, KaufmanF. European Society for Paediatric Endocrinology, Lawson Wilkins Pediatric Endocrine Society, International Society for Pediatric and Adolescent Diabetes, American Diabetes Association, European Association for the Study of Diabetes: Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2007; 30:1653–1662.
4.
WeinzimerSA, AhernJH, DoyleEA, VincentMR, DziuraJ, SteffenAT, TamborlaneWV. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics, 2004; 114:1601–1605Erratum in: Pediatrics 2004;115:518.
5.
PryceR. Diabetic ketoacidosis caused by exposure of insulin pump to heat and sunlight [lesson of the week]BMJ, 2009; 338:a2218.
6.
HanasR, LindgrenF, LindbladB. A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes, 2009; 10:33–37.
7.
VimalavathiniR, GitanjaliB. Effect of temperature on the potency & pharmacological action of insulin. Indian J Med Res, 2009; 130:166–169.
8.
ChandlerC, GryniewiczCM, PringleT, CunninghamF. Insulin temperature and stability under simulated transit conditions. Am J Health Syst Pharm, 2008; 65:953–963.
